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ARTICLE INFO                                          ABSTRACT 
 
 
 
 
Background: Chemoresistanceinvolving P-gp / MDR1 as uncertain factors affect the clinical 
response after the administration of neoadjuvant chemotherapy NAC) regimen Cyclophosphamid-
Doxorubicin-5FU CDF). Response to chemotherapy can be assessed by changes in mRNA expression 
of MDR1 gene due to DNA damage in the cancer cell DNA synthesis by examination of quantitative 
Real Time PCR qRT-PCR). Objective: Knowing the direction of change in MDR1 mRNA expression 
before and after administration of NAC regimen CDF on Local advanced breast cancer LABC) based 
clinical response. 
Method: Longitudinal observation with cohort prospective design of 20 samples before and after 
NAC regimen CDF with assessing the expression of MDR1 mRNA in LABC by qRT-PCR 
examination. Expression MDR1 mRNA analysis by T test independent, paired T-test, Chi-Square 
Test. 
Results: qRT-PCRExamination of 20 samples pre and post NAC regimen CDF showed that a decline 
of MDR1 mRNA expression p <0.05. In the clinical response responsive decreased of MDR1 mRNA 
expression p<0.05 while nonresponsive decrease MDR1 mRNA p> 0.05. Increased of MDR1 mRNA 
expression in nonresponsive clinical response was 38.5% 
Conclusion: There was a decrease significantly of MDR1 mRNA expression both before and after 
NAC regimen CDF as well as on clinical response responsive MDR1 mRNA expression before NAC 
regimen CDF as a predictor of response to chemotherapy. 
 
 
 
 
 
 
INTRODUCTION 
 
The number of new cases in the USA in 2013 an estimated 232 
340 newly diagnosed invasive breast cancer (Desantis et al., 
2013). The incidence of local advanced breast cancer LABC) 
in Indonesia gained 40-80% (Murray et al., 2012) whereas in 
developed countries obtain 20-30% of breast cancer have 
metastatic or locally advanced disease, and another 30% have 
recurrences or metastases (Chia, 2008). LABC is a breast 
cancer that is inoperable and who poorly survivalwith 
monotherapy (Vishnukumar, 2013). Management of LABC 
there is a tendency to change from radical surgery into a 
multimodality approach involving surgery, radiotherapy and 
chemotherapy (Taheri, 2013). The main problem in the 
treatment of breast cancer is the development of resistance to 
chemotherapeutic agents (Luqmani, 2008) that the mechanism 
involves changes in the expression of P-gp/MDR1 (Gonzalez-
Angulo et al., 2007).  
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In general, systemic therapies responded initially to 90% in 
primary breast cancer and 50% in metastases, but for a time 
period occurs progressive (Yardley et al., 2013). Although the 
role of Pgp/MDR1 in inducing drug resistance in cancer has 
been studied clinically, gene expression MDR1 in breast cancer 
is unclear, and the data is still controversial (Luqmani, 2008). 
Resistance is caused by tumor cells are resistant or Multidrug-
Resistant MDR) to various chemotherapy drugs that can cause 
treatment failure more than 90% in breast cancer who had 
metastasis and disease increased progressively over a period of 
less than one year (Martin et al., 2014). Resistance can occur 
intrinsic or acquired through multiple mechanisms, complex 
and not exclusive (Iwao, 2001). Response to chemotherapy can 
be assessed by changes in expression of gene mRNA its caused 
by the mRNA has the genetic code and can be assessed in real 
gene expression changes with quantitative Real Time PCR 
qRT-PCR) examination with high accuracy (Hammond, 2010) 
compared to the Immunochemistry IHC).  qRT-PCR one of the 
methods that are sensitive, efficient, fast and reproducible to 
measure gene expression and can be used to measure the 
quantity of mRNA levels (Taheri, 2013).  
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Rate biomarker changes after therapy NAC as an evaluation of 
the efficiency and also used for guiding the handling of the 
breast cancer (Dede, 2013). Neoadjuvant chemotherapy 
regimen changes biological tumor marker or causing tumor 
fraction in which the selection of biologically different from 
chemotherapy-naïve tumor (Boom, 1990). Examination of the 
changes in biomarker expression levels of genes mRNA by 
qRT-PCR cause the reason and the focus of this research in the 
genomics era so that changes in biomarkers before and after 
NAC regimen CDF can be used to guide clinicians in planning 
treatment as predictive and prognostic factors. 
 
METHODS AND SAMPLES 
 
This research was conducted longitudinal observation with 
cohort prospective design, the sample collection with a 
purposive sampling a number of 20 samples before and after 
NAC regimen CDF in Wahidin Sudirohusudo Hospital, 
Makassar  South Sulawesi, Indonesia. NAC regimen CDF is 
given before surgery for 3 cycles Cyclophosphamide 500 
mg/m2, Doxorubicin 50mg/m2, 5-fluorouracil 500 mg/m2 at 
intervals of every three weeks. The tissue sample was taken 
from an incisional biopsy before NAC regimen CDF and a 
mastectomy in patients LABC responsive while the 
nonresponsive LABC samples were taken by core biopsy. 
Chemotherapy response was measured with calipers in cm by 
RECIST Response Evaluation Criteria in Solid Tumors). The 
response to chemotherapy is classified into two parts: a) Non 
Responsive, RECIST: stable disease and progressive disease. If 
the reduced tumor size <30%, a fixed size, the size increases or 
discovered a new tumor. b) Responsive, RECIST: Partial 
response and Complete response: Tumor massdisappeared, or 
at least the reduction occurred tumor size by up to 30% as 
measured by bi-dimensional and not found a new tumor. 
Etichal Clearance obtained from research Committee, Faculty 
of medicine, Hasanuddin University, Makassar, Indonesia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quantitative real-time PCR Assay 
 
Quantitative real-time PCR system Applied Biosytems) using 
Power SYBR®. Green PCR Mix Applied Biosytems). 
Detecting gene MDR1 mRNA using a specific premier forward 
and reverse PCR protocol: Performed with the DNA 
replication cycle of 94°C for 3 minutes, the cycle is repeated 
38 times at 54oC 30 seconds). Detecting GAPDH gene using 
the forward / sense primer MDR1 mRNA: a) Forward: 5'-
TGACATTTATTCAAAGTT AAAAGCA-3'; PCR protocol: 
94°C 10 min); 32 cycles of 54oC 30 seconds) and 
reverse/antisense primer: MDR1-reversed: 5'-
TAGACACTTTATGCAAACATTTCAA-3'. in accordance 
with the protocol Tomomi Yajima. 
 
Data analysis 
 
Data were analyzed with SPSS Statistics Packed for Social 
Science) version 22. Bivariable analysis was used to test the 
significance of variables mean difference before and after 
chemotherapy regimen CDF. If the distribution of the normal 
distribution of data used parametric independent t-test, paired T 
test and Chi Quare test. 
 
RESULTS 
 
MDR1 mRNA expression before chemotherapy regimen CDF 
with mean is 11.530.69 and after chemotherapy mean CDF is 
10.322,32. There was a decrease MDR1 mRNA expression 
before and after chemotherapy regimen CDF showed a 
significant difference with p <0.05. The table 2 shows that the 
clinical response nonresponsive mean MDR1 mRNA 
expression decreased after chemotherapy CDF of 11.790.87 
pg/ml to 10.512.76 pg/ml. While the decline responsive tumor 
response after chemotherapy CDF of 11.390.55 pg/ml to 
10.232.16 pg/ml. It was found also that the MDR1 mRNA 
expression was higher in tumor nonresponsive. T Test paired 
result that tumor nonresponsive decrease  
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Table 1. ER mRNA expression of before and after chemotherapy CDF on LABC 
 
Variable Mean Difference 95%CI p-value 
mRNA MDR1 
Before chemotherapy n=20 
After   chemotherapy n=20 
 
11,530,69 
10,322,32 
 
1,201,80 
 
 
0,36-2,05 
 
0,01* 
Clinical response 
Before chemotherapy n=20 
After   chemotherapy n=20 
 
10.203.70 
5.552.85 
 
4.653.01 
 
3.24-6,06 
 
0.00* 
                                                   Note: p* = significant p< 0.05 
 
Table 2. Expression of MDR1 RNA based Clinical Response 
 
Variable Mean Difference 95%CI p-value 
Nonresponsive 
mRNA MDR1 Before chemotherapy  n=7 
After chemotherapy   n=7 
 
11.790.87 
10.51 2.76 
 
 
1.281.99 
 
 
0.56-3.12 
 
 
0.139 
Responsive 
mRNA MDR1 
Before chemotherapy n=13 
After chemotherapy  n=13 
 
 
11.390.55 
10.232.16 
 
 
 1.161.78 
 
 
 
 0.09-2.23 
 
 
0.036 
p= T  pair test     
 
Table 3. The MDR1 mRNA expression before chemotherapy CDF against tumor response after  
the administration of neoadjuvant chemotherapy CDF on LABC 
 
Variable Expression mRNA MDR1 Value p (1-side) 
Risk (11.38750) No risk (<11.38749) 
 
n (%) Risk Estimates n (%) Risk Estimates 
 
 
Clinical 
response  
N 
Nonresponse  
5 (38,5) 1,161 2 (28.6) 0,743 
0,526 
RResponse 8 (61.5)  5 (71.4)  
 
Total 
13 (100)  7 (100)  
 
MDR1 mRNA expression before and after NAC regimen CDF 
is not significant p = 0.14 whereas in tumors responsive to 
significant p = 0:04, so it can be stated that the effect of 
chemotherapy regimen CDF to clinical response decreased 
mean mRNA ficantly in responsive tumors. Table 3 shows that 
higher MDR1 mRNA expression the proportion of 
nonresponse tumor incidence amounted to 38.5% 5 of 13 
LABC), while the responsive tumor incidence the proportion of 
61.5%. MDR1 mRNA probability of high risk for tumor 
response by 1,161 times. Furthermore, mRNA MDR1 
expression lower incidence of proportion tumor nonresponse 
was 28.6% 2 of 7 LABC) and tumor responsiveness was 71.4% 
with risk estimates for 0,743 times. 
 
DISCUSSION 
 
This study showed that decreased of MDR1 mRNA expression  
allegedly caused cancer cells are sensitive have apoptosis and 
left resistant cell clones. Biomarker changes after giving NAC 
regimen CDF allegedly due to changes in the characteristics of 
epigenetic gene MDR1. Examination of DNA methylation 
profile on MDR1 gene therapy after the administration of 
Doxorubicin on LABC obtained absence of methylation in the 
promoter regions of genes MDR1 (Burger, 2003). Abnormal 
methylation can cause MDR1 gene transcription process in 
forming the lower MDR1 mRNA. Furthermore, this study 
showed a decrease in mRNA MDR1 expression in 
nonresponsive group 11.790.87) to 10.512.76) and  MDR1 
mRNA expression was higher in tumor nonresponsive. 
Similarly, the results of another study showed a higher MDR1 
in tumor nonresponsive (Luqmani, 2008); (Korn, 2002). 
Research on P-gp / MDR1, Zhang et al, 2014 reported that 
46.4% breast cancer showed increased expression of P-gp in 
tumors after NAC nonresponsive disease progression). This 
means, first, that anthracycline regimen is substrate of P-gp, so 
that the tumor cells that P-gp negative more sensitive and 
killed by NAC therapy while the expression of P-gp high 
tumor will survive.  
 
Second, acquired drug resistance after exposure to the NAC 
therapy. Regardless of whether the expression of P-gp primary 
or acquired, expressionP-gp is high both in the pre and post 
NAC NAC therapy as a predictor of poor treatment outcome. 
Examination of the DNA methylation biomarker profile after 
the administration of Doxorubicin therapy in treatment 
Doxorubicin response LABC obtained absence of methylation 
in the promoter regions of genes MDR1. Hipomethylation 
promoter MDR1 gene associated with TP53 mutation, a tumor 
with a CpG island region hipomethylation MDR1 associated 
with mutations in the loop domains L2 / L3 is an area that is 
associated with resistance to anthracycline therapy base, 
causing the expression of positive MDR1 impact on the clinical 
response nonresponsive. The absence of methylation in the 
promoter on MDR1 associated with disease progression during 
therapy Doxorubicin reverse DNA methylation status of the 
promoter MDR1 associated with survival (Burger, 2003). NAC 
regimen CDF in responsive tumors showed that a decline in 
MDR1 mRNA expression decreased significantly in clinical 
response responsive. Clinical response responsive occur due to 
various factors that contribute beyond this study. Research 
Korn et al., 2002 showed significant increase in gene 
expression before and after chemotherapy regimen of 
anthracycline base, in this case the gene cyclin-kinase inhibitor 
dependents p21) (Modlich, 2004; Vousden, 2000). The 
increase genes transcription that describe the response of the 
p53 gene to Doxorubicin induces DNA damage that causes cell 
cycle break (Zhang, 2014). Furthermore, it also obtained 
Thymidylate synthase gene expression changes immediately 
after neoadjuvant chemotherapy Doxorubicin and 
cyclophosphamide) (Vousden, 2000). Thymidylate synthase 
TS) plays an important role in the early stages of DNA 
biosynthesis. In this study, the chemotherapy regimen given 
CDF, where 5 Fu as inhibitors of the enzyme thymidylate 
synthase thus antimetabolite that irreversibly inhibit TS 
causing DNA damage. 
 
The results showed that administration of NAC regimen CDF 
on the high expression of MDR1 mRNA proportion of 
incidence tumor nonresponsivewas 38.5%.  Status of P-gp is an 
important factor influencing the pathological complete 
response manner pCR). Changes in the expression of P-gp, 
from negative to positive after the NAC indicate drug 
resistance as a result of chemotherapy. The expression of P-gp 
were low before NAC associated with improvement in pCR 
figures. This suggests that P-gp is a predictive tool for the 
benefit of NAC. Furthermore, the increase in P-gp significantly 
after NAC there are trends tumor nonresponsive pNR). P-gp 
expression status provides information prognostic for NAC 
therapy (Tanei, 2011). The study showed that 72 %) of the 103 
non-pCR patients LABC P-gp expression before and after 
NAC is useful as a prognostic factor in LABC. 
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